OAT3- medieret transport af sitagliptin hæmmes in vitro af probenecid, selvom risikoen for klinisk relevante interaktioner anses for at være lav.
OAT3 mediated transport of sitagliptin was inhibited in vitro by probenecid, although the risk of clinically meaningful interactions is considered to be low.